Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas

BACKGROUND: Recent knowledge of psoriasis pathogenesis has led to the development of selective drugs. Among these, brodalumab is a monoclonal antibody targeting the interleukin (IL)-17A receptor approved for the treatment of moderate-to-severe plaque psoriasis. Biologics may be considered in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Cacciapuoti, Sara, Potestio, Luca, Guerrasio, Gianluca, Fabbrocini, Gabriella, Scalvenzi, Massimiliano, Ruggiero, Angelo, Caiazzo, Giuseppina, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541085/
https://www.ncbi.nlm.nih.gov/pubmed/37780688
http://dx.doi.org/10.2147/CCID.S423234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541085/
https://www.ncbi.nlm.nih.gov/pubmed/37780688
http://dx.doi.org/10.2147/CCID.S423234

Ejemplares similares